Medicare Enrolled

Dr. Jed Freeman, M.D.

Hematology & Oncology · Redding, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
2510 AIRPARK DR, Redding, CA 96001
5302428822
In practice since 2007 (19 years)
NPI: 1275669038 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Freeman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Freeman? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Freeman

Dr. Jed Freeman is a hematology & oncology specialist in Redding, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Freeman performed 10,280 Medicare services across 1,442 unique beneficiaries.

Between the years covered by Open Payments, Dr. Freeman received a total of $1,104 from 19 pharmaceutical and/or device companies across 34 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Freeman is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 29% volume in CA $1,104 industry payments

Medicare Practice Summary

Medicare Utilization ↗
10,280
Medicare services
Top 29% in CA for hematology & oncology
1,442
Unique beneficiaries
$28
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~541 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Pembrolizumab injection (Keytruda) 5,400 $43 $99
Anti-nausea injection (fosaprepitant)
An injection of fosaprepitant, a medication used to prevent nausea and vomiting.
2,250 $0 $4
Dexamethasone injection (steroid)
An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram.
469 $0 $0
Complete blood count (CBC) with differential
An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells.
360 $8 $24
Comprehensive metabolic blood panel
A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers.
309 $10 $36
Anti-nausea injection (Aloxi/palonosetron) 290 $1 $41
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
255 $8 $10
Intravenous injection of additional new drug or substance
Administration of an additional new medication or substance directly into a vein.
125 $11 $97
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
119 $66 $336
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
106 $94 $450
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
90 $94 $412
Immunoglobulin level test
A blood test that measures the level of gammaglobulins, which are immune system proteins.
69 $9 $21
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
50 $38 $204
Lactate dehydrogenase (LDH) level test
A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease.
41 $6 $22
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
41 $134 $635
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
38 $11 $76
Immunoassay substance measurement
A laboratory test that uses immunoassay techniques to measure the level of a specific substance in a sample.
36 $17 $52
Thyroid stimulating hormone (TSH) test
A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function.
36 $16 $40
Additional sequential IV infusion, 1 hour or less
This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less.
28 $21 $93
Diphenhydramine injection, up to 50 mg
An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams.
28 $1 $1
Magnesium level test
A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess.
26 $7 $27
Ferritin level test (iron stores)
A blood test that measures the level of ferritin, a protein that stores iron in the body.
24 $13 $66
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
21 $21 $90
Intravenous infusion of new drug or substance, 1 hour or less
This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less.
21 $47 $198
Carcinoembryonic antigen (CEA) level test
A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer.
19 $19 $64
Free thyroxine (T4) test
A blood test that measures the level of free thyroxine, a thyroid hormone, in the bloodstream.
18 $9 $20
Iron level test 11 $6 $21
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.4% high complexity
83.9% medium
14.8% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$1,104
Total received (2018-2024)
Avg $158/year across 7 years
Bottom 35% in CA for hematology & oncology
19
Companies
34
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$870 (78.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$234 (21.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$184
2023
$203
2022
$22
2021
$342
2020
$114
2019
$127
2018
$112

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$39
E.R. Squibb & Sons, L.L.C.
$36
Ipsen Biopharmaceuticals, Inc
$30
Regeneron Healthcare Solutions, Inc.
$30
Novartis Pharmaceuticals Corporation
$28
Astellas Pharma US Inc
$22
Top 3 companies account for 56.7% of 2024 payments
All-time payments by company (2018-2024) ›
Incyte Corporation
$166
AstraZeneca Pharmaceuticals LP
$128
Astellas Pharma US Inc
$117
Kite Pharma, Inc.
$112
Genentech USA, Inc.
$88
PFIZER INC.
$76
E.R. Squibb & Sons, L.L.C.
$49
Novartis Pharmaceuticals Corporation
$45
Eisai Inc.
$41
GENZYME CORPORATION
$38
Celgene Corporation
$36
Janssen Biotech, Inc.
$34
Ipsen Biopharmaceuticals, Inc
$30
Regeneron Healthcare Solutions, Inc.
$30
ABBVIE INC.
$29
Seagen Inc.
$25
GlaxoSmithKline, LLC.
$24
Octapharma USA, Inc.
$22
Amgen Inc.
$15
Top 3 companies account for 37.2% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · Avastin · BOSULIF · DARZALEX · ELITEK · ELREXFIO · IBRANCE · IMFINZI · JAKAFI · KISQALI · LIBTAYO · LUPRON DEPOT · LYNPARZA · Lenvima · MONJUVI · Nplate · OPDIVO · Onivyde · PANZYGA · Pomalyst · SARCLISA · SCEMBLIX · Vyloy · Yescarta · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (79%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a hematology & oncology specialist in Redding?
Compare hematology & oncology specialists in the Redding area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
4
Per 100K population
2.2
County median income
$71,931
Nearest hospital
MERCY MEDICAL CENTER REDDING
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Freeman is a mixed practice specialist, with above-average Medicare volume (top 29% in CA), with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Freeman experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Freeman performed 5,400 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Freeman receive payments from pharmaceutical companies?
Yes. Dr. Freeman received a total of $1,104 from 19 companies across 34 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Freeman's costs compare to other hematology & oncology specialists in Redding?
Dr. Freeman's average Medicare payment per service is $28. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Freeman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →